Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists

The article by Pae et al., titled "LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy," provides valuable insights into the differential effects of LHRH antagonists and agonists on testosterone recovery in prostate cancer patients undergoing androgen deprivation therapy. While the study highlights the statistically significant accelerated recovery of testosterone with LHRH antagonists, several limitations warrant further discussion. Notably, the study does not adequately address the variability in the duration and formulations of LHRH agents (e.g., 1-month, 3-month, and 6-month formulations), which may influence recovery times. Existing evidence suggests that long-acting formulations are associated with prolonged recovery, raising questions about whether the observed differences are due to pharmacological properties or formulation duration. The clinical relevance of faster testosterone recovery remains uncertain, as the study does not evaluate its impact on patient-reported outcomes such as quality of life, sexual function, or metabolic health. Future research should focus on stratifying analyses by formulation type and duration and assessing the clinical implications of testosterone recovery on patient-centered outcomes to enhance the applicability of these findings to clinical practice.